Improvement of replication fidelity by certain mesalazine derivatives

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1331-1338

  Honeder, Clemens ^a   Campregher, Christoph ^a   Zens, Bettina ^a   Scharl, Theresa ^b,c   Gasche, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Chemoprevention; Colorectal cancer; Microsatellite instability; Replication fidelity

Indexed keywords

3 (4 AMINOPHENYL) 2 ETHOXYPROPANOIC ACID; 3 (4 AMINOPHENYL) 2 METHOXYPROPIONIC ACID; 5 AMINO 2,3 DIHYDROBENZOFURAN 7 CARBOXYCLIC ACID; 5 AMINO N HYDROXY 2 METHOXYBENZAMIDE; 6 AMINO 2,2 DIMETHYL BENZO[1,3]DIOXIN 4 ONE; ANTINEOPLASTIC AGENT; MESALAZINE; SCAVENGER; SUPEROXIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIVISION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG EFFECT; DRUG STRUCTURE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTICARCINOGENIC AGENTS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; HCT116 CELLS; HT29 CELLS; HUMANS; MESALAMINE; MUTATION; NUCLEAR PROTEINS; OXIDATIVE STRESS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SUPEROXIDES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860299757     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1381     Document Type: Article

References (28)

1. Svartz N: Salazopyrin - a new sulfanilamide preparation. A. Therapeutic result in rheumatoid arthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations on treatment with sulfanilamide preparations. Acta Med Scand 110: 577-590, 1942.
2. Azad Khan AK, Piris J and Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2: 892-895, 1977.
3. Lyakhovich A and Gasche C: Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 31: 202-209, 2010.
4. Rubin DT, Cruz-Correa MR, Gasche C, Jass JR, Lichtenstein GR, Montgomery EA, Riddell RH, Rutter MD, Ullman TA, Velayos FS and Itzkowitz S: Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 14: 265-274, 2008. (Pubitemid 351288050)
5. Stolfi C, Pellegrini R, Franze E, Pallone F and Monteleone G: Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol 14: 4434-4439, 2008.
6. Kennedy M, Wilson L, Szabo C and Salzman AL: 5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med 4: 437-443, 1999.
7. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F and Monteleone G: Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 75: 668-676, 2008.
8. Campregher C, Luciani MG, Biesenbach P, Evstatiev R, Lyakhovich A and Gasche C: The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity. Inflamm Bowel Dis 16: 576-582, 2010.
9. Kaiser GC, Yan F and Polk DB: Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 116: 602-609, 1999. (Pubitemid 29106768)
10. Swidsinski A, Loening-Baucke V, Bengmark S, Lochs H and Dorffel Y: Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis 13: 51-56, 2007. (Pubitemid 46080009)
11. Chu EC, Chai J, Ahluwalia A and Tarnawski AS: Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment Pharmacol Ther 25: 1443-1449, 2007. (Pubitemid 46848890)
12. Monteleone G, Franchi L, Fina D, Caruso R, Vavassori P, Monteleone I, Calabrese E, Naccari GC, Bellinvia S, Testi R and Pallone F: Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 13: 202-211, 2006. (Pubitemid 43102204)
13. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF and Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201: 1205-1215, 2005. (Pubitemid 40629065)
14. Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP and Richel DJ: Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 27: 2371-2382, 2006. (Pubitemid 44884094)
15. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I and Schmiegel W: Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24: 443-451, 2003. (Pubitemid 36432639)
16. Gasche C, Goel A, Natarajan L and Boland CR: Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res 65: 3993-3997, 2005. (Pubitemid 40775634)
17. Luciani MG, Campregher C, Fortune JM, Kunkel TA and Gasche C: 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 132: 221-235, 2007. (Pubitemid 46108738)
18. Gasche C, Chang CL, Natarajan L, Goel A, Rhees J, Young DJ, Arnold CN and Boland CR: Identification of frame-shift intermediate mutant cells. Proc Natl Acad Sci USA 100: 1914-1919, 2003. (Pubitemid 36254548)
19. Campregher C, Luciani MG and Gasche C: Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon epithelial cells. Gut 57: 780-787, 2008. (Pubitemid 351716971)
20. Natarajan L, Berry CC and Gasche C: Estimation of spontaneous mutation rates. Biometrics 59: 555-561, 2003. (Pubitemid 37093394)
21. Hussain SP, Hofseth LJ and Harris CC: Radical causes of cancer. Nat Rev Cancer 3: 276-285, 2003. (Pubitemid 37328863)
22. Chini CC and Chen J: Human claspin is required for replication checkpoint control. J Biol Chem 278: 30057-30062, 2003.
23. Lee J, Kumagai A and Dunphy WG: Claspin, a Chk1-regulatory protein, monitors DNA replication on chromatin independently of RPA, ATR, and Rad17. Mol Cell 11: 329-340, 2003. (Pubitemid 36293828)
24. Stolfi C, Sarra M, Caruso R, Fantini MC, Fina D, Pellegrini R, Palmieri G, Macdonald TT, Pallone F and Monteleone G: Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine. Gastroenterology 138: 221-230, 2010.
25. Campregher C, Honeder C, Chung H, Carethers JM and Gasche C: Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats. Clin Cancer Res 16: 1950-1956, 2010.
26. Stolfi C, Fina D, Caruso R, Caprioli F, Fantini MC, Rizzo A, Sarra M, Pallone F and Monteleone G: Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis 29: 1258-1266, 2008. (Pubitemid 351958707)
27. Glaab WE, Hill RB and Skopek TR: Suppression of spontaneous and hydrogen peroxide-induced mutagenesis by the antioxidant ascorbate in mismatch repair-deficient human colon cancer cells. Carcinogenesis 22: 1709-1713, 2001. (Pubitemid 32952151)
28. Kucherlapati MH, Lee K, Nguyen AA, Clark AB, Hou H Jr, Rosulek A, Li H, Yang K, Fan K, Lipkin M, Bronson RT, Jelicks L, Kunkel TA, Kucherlapati R and Edelmann W: An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology 138: 993-1002, 2010.